This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

This study has been completed.
Johns Hopkins All Children's Hospital
Nemours Children's Clinic
Information provided by (Responsible Party):
Columbia University Identifier:
First received: November 6, 2009
Last updated: July 11, 2017
Last verified: July 2017

Primary Objective:

1. To evaluate the safety of orally administered Lactobacillus plantarum strains 299 and 299v, a probiotic, in patients undergoing allogeneic myeloablative HSCT, as measured by incidence of Lactobacillus plantarum bacteremia.

Secondary Objectives:

  1. To investigate the feasibility of administering Lactobacillus plantarum 299 and 299v to children and adolescents undergoing HSCT.
  2. To describe the overall incidence of bacteremia in HSCT patients who have been administered Lactobacillus plantarum.
  3. To describe the overall incidence of acute graft versus host disease (GVHD) in HSCT patients who have been administered Lactobacillus plantarum.

Condition Intervention Phase
Hematopoietic Organs; Disorder Drug: Lactobacillus plantarum strains 299 and 299v Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: A Limited Institution Pilot Trial Evaluating the Safety of Administering the Probiotic, Lactobacillus Plantarum, to Children and Adolescents Undergoing Allogenic Hematopoietic Stem Cell Transplantation (HSCT) - A Pilot Study

Resource links provided by NLM:

Further study details as provided by Columbia University:

Primary Outcome Measures:
  • Number of Lactobacillus Plantarum Bacteremia Infections [ Time Frame: 36 days (day -7 to +28 of HSCT) ]

Secondary Outcome Measures:
  • Adherence With the Prescribed Dose, Measured as the Percentage of Prescribed Probiotic Doses [ Time Frame: 22 days (day -7 to +14 of HSCT) ]
    To determine the feasibility of administration of L. plantarum 299 and 299v. The treatment is considered feasible for a patient if he/she received at least 50% of the probiotic dose (>= 11 days of treatment).

  • Number of Non-lactobacillus Infections [ Time Frame: 36 days (day -7 to +28 of HSCT) ]
    To determine incidence of bacteremia in HSCT patients who have been administered lactobacillus plantarum.

  • Number of Acute Graft Versus Host Disease (GVHD) Events in HSCT Patients Who Have Been Administered Lactobacillus Plantarum [ Time Frame: Up to Day +100 of HSCT ]

Enrollment: 31
Study Start Date: February 2010
Study Completion Date: October 2014
Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lactobacillus plantarum
There is a single intervention arm in this study. Target accrual for the intervention is 30 subjects. Subjects receive supplementation with Lactobacillus plantarum strains 299 and 299v.
Drug: Lactobacillus plantarum strains 299 and 299v

Patients will receive a daily dose of Lactobacillus plantarum: 1 x10^8 CFU/kg/day. This supplement will be supplied in sachets of powder and will be mixed in water (certain water-based liquid) that is no warmer that 37o C.

Colony forming units (CFU)

Other Name: Probiotics

Detailed Description:
Myeloablative regimens are the backbone of hematopoietic stem cell transplantation (HSCT) and are associated with prolonged periods of cachexia/anorexia, nausea/vomiting, mucositis, and compromised gut integrity (CGI). The toxicities associated with HSCT often lead to prolonged periods of poor oral intake and may result in overt malnutrition. CGI decreases oral tolerance to foods, reduces Quality of Life (QOL) and functional status, delays the transition from the hospital to home setting, and increases the risk of the development of gut-derived infections. Probiotics are nutritional supplements that contain a defined amount of viable microorganisms and upon administration confer a benefit to the host. Clinical trials in adults receiving organ transplants have found probiotics decrease the incidence of infection, the duration of antibiotic use, the incidence of multiorgan failure and systemic inflammation. Children and adolescents undergoing HSCT, experience similar clinical challenges suggesting probiotics may have a therapeutic value in the setting of HSCT. This study is to evaluate the safety and feasibility of administering probiotics to children and adolescents undergoing HSCT.

Ages Eligible for Study:   2 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients undergoing myeloablative allogeneic HSCT will be eligible. The source of stem cells can be from bone marrow, umbilical cord blood or cytokine mobilized peripheral blood. Donor can be human leukocyte antigen (HLA) matched sibling or parent, a related donor mismatched for a single HLA locus (class I or II), unrelated marrow or peripheral blood stem cell donor, or unrelated cord blood at least 4/6 antigen match (Class 1 or II).
  • Patients of either gender and between 2 and 17.99 years of age
  • Patients receiving any type of GVHD prophylaxis are eligible.

Exclusion Criteria:

  • Patients who have self-prescribed probiotics within 3 months of starting the conditioning regimen for stem cell transplant (consumption of yogurt products is allowed).
  • Patients with known allergy to oats.
  • Patients who have had any type of gut damage within the past three months; such as, previous bowel perforations; previous episode of Grade 4 neutropenic colitis or typhlitis.
  • Patients with inflammatory bowel syndrome, short small bowel syndrome, Crohns Disease, Ulcerative Colitis, and patients with a history of bowel resections.
  • Patients who have undergone a previous allogeneic HSCT.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01010867

United States, Florida
Nemours Children's Clinic
Jacksonville, Florida, United States, 32207
All Children's Hospital
Saint Petersburg, Florida, United States, 33701
United States, New York
Columbia Universtiy Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
Johns Hopkins All Children's Hospital
Nemours Children's Clinic
Principal Investigator: Michael Neider, MD Johns Hopkins All Children's Hospital
Principal Investigator: Monica Bhatia, MD Columbia University
Principal Investigator: Elena J Ladas, PhD, RD Columbia University
  More Information

Responsible Party: Columbia University Identifier: NCT01010867     History of Changes
Other Study ID Numbers: AAAE0846
Study First Received: November 6, 2009
Results First Received: November 9, 2015
Last Updated: July 11, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Columbia University:
Hematopoietic Stem Cell Transplantation
Pediatrics processed this record on September 19, 2017